

STREAMLINED CLINICAL TRIALS and REGULATORY APPROACHES

WE ARE WE NOW

LIMITED CLINICAL TRIAL INFRASTRUCTURE CLOSE TO AFFECTED COMMUNITIES LEADS TO INEQUITY

UNEVEN MATURITY OF REGULATORY AGENCIES WORLDWIDE IMPACTS ACCESS TO PRODUCTS

OUR VISION

EFFICIENT AND SMOOTH DEVELOPMENT OF PRODUCTS

WITH MORE REGULATORY CAPACITY

FOR PEOPLE TO HAVE MORE ACCESS TO PRODUCTS

INFRASTRUCTURE CLOSER TO COMMUNITIES,

AND COORDINATED STAKE HOLDERS THAT IMPROVE SPEED OF THE RESPONSE

EFFICIENT FUNDING.

